Erythropoietin for anemia in people on dialysis
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests whether a medication called erythropoietin (a hormone that helps your body make red blood cells) can improve hemoglobin levels in people on dialysis. It also looks at whether metabolic syndrome (a group of conditions like high blood pressure and high blood sugar) makes the medicine less effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be on regular hemodialysis for at least 3 months
- You must not have cancer, severe heart or liver disease, or a recent stroke
- You must not have an active infection or autoimmune disease
- If you are female, you must not be pregnant, on hormone therapy, or have polycystic ovarian syndrome
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study tests whether taking a probiotic (a healthy bacteria supplement) can help people with kidney failure on dialysis respond better to erythropoietin, a medicine that treats anemia (low red blood cells). If the probiotic works, it could reduce the need for high doses of this medicine and improve your energy levels.
This study compares two similar medicines used to treat anemia (low red blood cells) in people with advanced kidney disease who are on dialysis. The goal is to see if both work equally well.
This study looks at why some people on dialysis don't respond well to anemia medicines (called ESAs). It aims to help doctors understand and better treat anemia in dialysis patients.
This study tests an experimental medicine for anemia in people with kidney disease who are on dialysis. It aims to see if it can help raise blood counts safely compared to standard treatments.
This study compares two anemia medicines for people with chronic kidney disease (CKD) who are not on dialysis. It aims to find a more convenient pill option (daprodustat) versus a commonly used injection (epoetin alfa).
Hear when a new Erythropoietin Resistant Anemia (EPO Resistant Anemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.